1989
DOI: 10.1002/med.2610090205
|View full text |Cite
|
Sign up to set email alerts
|

Adenosine antagonists

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
14
0
1

Year Published

1992
1992
1998
1998

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 42 publications
(16 citation statements)
references
References 118 publications
1
14
0
1
Order By: Relevance
“…The potency order of adenosine analogues in hyperpolarizing the SCG and inhibiting the depolarization caused by muscarine was characteristic of that generally observed for Al-adenosine receptor agonists and differed markedly from the order characteristic of A2-adenosine receptor agonists as outlined in the Introduction and as described and reviewed by Williams (1989). Both the absolute potency and relative order of potency of adenosine analogues in hyperpolarizing ganglia are similar to values reported for tissues containing Al-adenosine receptors (Daly, 1982).…”
Section: Discussionsupporting
confidence: 57%
See 1 more Smart Citation
“…The potency order of adenosine analogues in hyperpolarizing the SCG and inhibiting the depolarization caused by muscarine was characteristic of that generally observed for Al-adenosine receptor agonists and differed markedly from the order characteristic of A2-adenosine receptor agonists as outlined in the Introduction and as described and reviewed by Williams (1989). Both the absolute potency and relative order of potency of adenosine analogues in hyperpolarizing ganglia are similar to values reported for tissues containing Al-adenosine receptors (Daly, 1982).…”
Section: Discussionsupporting
confidence: 57%
“…More recently the relative affinity of N6-substituted adenosine analogues in binding studies has been examined by Daly et al (1986) and Ukena et al (1987) and it was proposed that the adenosine receptor analogues 5'-N-ethylcarboxamidoadenosine (NECA), N6-cyclohexyladenosine (CHA), N6-cyclopentyladenosine (CPA), R( + )and S(-)-N6-phenyl-isopropyladenosine (R-PIA and S-PIA), 2-chloroadenosine (2CA) and 2-phenylaminoadenosine (PAA) would be useful in functional studies for defining receptor subtypes. In both functional studies and binding studies a potency order of adenosine analogues for A,-adenosine receptors was CPA > R-PIA > 2CA > NECA > S-PIA > PAA and for A2adenosine receptors was NECA > 2CA > PAA = R-PIA > CPA > S-PIA (Williams, 1989).…”
Section: Introductionmentioning
confidence: 93%
“…Also, the nonselective adenosine receptor antagonist, 8-SPT (which does not cross the blood-brain barrier; Evonuik et al, 1986) was ineffective in attenuating hypotensive responses to adenosine analogues in these experiments. 8-SPT has a far lower potency than 8-PT at adenosine Al receptors (Williams, 1989), and hence a comparison of potencies must take this into account. However, since 8-SPT was ineffective in these experiments and the doses of agonists used were insufficient to produce peripheral responses of this magnitude, it is unlikely that the effects of the adenosine agonists are occurring peripherally.…”
Section: Discussionmentioning
confidence: 99%
“…In organs or cell preparations, the R-PIA dose-response curve depicting cAMP production may be biphasic, characterized by inhibition of adenylate cyclase activity in the nanomolar range and by stimulation of CAMP production at micromolar concentrations. Compared with R-PIA, NECA is a more potent activator of the A2-site which stimulates adenylate cyclase and does not show inhibitory activity on this enzyme (Londos et al, 1980;Williams, 1989).…”
Section: Discussionmentioning
confidence: 99%